Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea
Evaluation of Efficacy of Botulinum Toxin Type A in the Treatment of Sialorrhea in the Patient Affected by Amyotrophic Lateral Sclerosis (ALS)
Sponsor: Hospices Civils de Lyon
A PHASE2 clinical study on Amyotrophic Lateral Sclerosis and Sialorrhea, this trial is completed. The trial is conducted by Hospices Civils de Lyon and has accumulated 6 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Feb 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hospices Civils de Lyon
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Angers, France , Bron, France , Caen, France , Clermont-Ferrand, France , Lille, France , Limoges, France , Marseille, France , Nancy, France , Nice, France , Paris, France and 3 more locations